Treatment Pattern of Acute Respiratory Tract Infections in General Practice with 3rd generation Oral Cefixime in Bangladesh

1970 ◽  
Vol 40 (1) ◽  
pp. 39-42
Author(s):  
SZ Hossain ◽  
RF Khan ◽  
UK Barua ◽  
MJ Sobhan

Respiratory tract infections (RTIs) are a major health problem in developing countries. RTIs are the most common reason for physician visits and prescription of antibiotics. Cefixime is quickly establishing as a potent broad-spectrum antibiotic with a variety of indications. This observational study was designed to describe the treatment pattern of third generation oral cefixime in managing RTIs in general practice. This noncontrolled, multicenter, observational registry was carried out from March 2009 to July 2010. During this period 2400 patients aged 3 years to 76 years suffering from RTIs were enrolled by general physicians throughout the country. Study variable were socio demographic, signs and symptoms, clinical diagnosis, investigations, antimicrobial prescribed and clinical outcome. Clinical outcome was determined based on improvement of signs and symptoms. Compliance, efficacy and tolerance were assessed on days 7 and 10. The enrolled patients were considered for analysis. The mean age was 26.59 (± 18.10) years and 62% of patients were male. Common presenting signs and symptoms were fever, cough, shortness of breath and increased sputum volume in 80%, 75%, 39%, and 12% respectively. From prescriptions, pneumonia, acute bronchitis, acute exacerbation of chronic bronchitis and lung abscess were the diagnosis in 42%, 26%, 24% and 3% of the prescriptions, respectively. Following the treatment with cefixime clinically cured, much improved and better were obtained in 77%, 21% and 2% respectively. Furthermore, the rate of adverse events were insignificant. The study showed clinical symptoms improved rapidly and high rates of clinical cure were achieved. More over, the rate of adverse events were relatively quite low. The results supports the use of cefixime for a variety of respiratory infections in adult and pediatric patients in Bangladesh. DOI: http://dx.doi.org/10.3329/bmj.v40i1.9962 BMJ 2011; 40(1): 39-42

1986 ◽  
Vol 14 (2) ◽  
pp. 110-114
Author(s):  
R Pauwels ◽  
J J Detiège

Nine hundred and eleven patients were admitted to a multicentre trial with bacampicillin (Penglobe®) in respiratory tract infections. Of these it was possible to evaluate 830 with respect to efficacy and side-effects. In most cases a dosage of 400 mg × 2 was used but in severe cases 800 mg × 2 was used. The clinical outcome was assessed as good for 79% of the patients, while 17% showed an improvement and 3% a failure. The tolerance was good with an over-all incidence of 8% side-effects, of which dyspepsia was the most common.


2005 ◽  
Vol 56 (5) ◽  
pp. 930-936 ◽  
Author(s):  
Annemiek E. Akkerman ◽  
Marijke M. Kuyvenhoven ◽  
Johannes C. van der Wouden ◽  
Theo J. M. Verheij

1984 ◽  
Vol 12 (3) ◽  
pp. 207-209
Author(s):  
S Kalachand

The clinical outcome of 143 patients presenting with acute respiratory tract infection and treated with oral amoxycillin is described. A clinical success rate of 92% was observed after 1 week's therapy with only one patient deteriorating whilst on treatment. Side-effects were mild and limited to 7% of patients.


Open Medicine ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. 362-365 ◽  
Author(s):  
Richard Kitz ◽  
Ute Martens ◽  
Egmont Zieseniß ◽  
Paul Enck ◽  
Markus Rose

AbstractSinusitis is a frequent complication of respiratory tract infections. Probiotics are perceived to be useful in infections, allergies, and inflammations. Our prospective trial stratified 204 children with recurrent rhinosinusitis by age (2–11 years, 54m:64f; 12–18 years, 39m:47f) and assigned them to standard treatment (antibiotics, anticongestants) or additional 60 days Symbioflor-1 (SF1; Enterococcus faecalis 1.5–4.5x107 CFU). The number of sinusitis episodes was lower in SF1-treated patients (2.52±0.91) than among controls (3.27±1.36; p=0.01). Mean duration of the first sinusitis episode was 11.9±8.6 days with SF1, whereas it was 16.1±12.9 days in the younger controls (p=0.023) and 9.86±5.05 days in the elder controls (n.s.). Duration of subsequent sinusitis episodes was also shorter in SF1 patients (15.2±13.6 days) compared with controls (22.7±14.8 days; p=0.030). No adverse events were observed. Probiotic Enterococcus faecalis adjuvant to conventional therapy can reduce the number and duration of rhinosinusitis episodes in children and adolescents.


Sign in / Sign up

Export Citation Format

Share Document